Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

MDS with Isolated Neutropenia or Thrombocytopenia. Incidence and Characteristics in the Groupe Francophone des Myélodysplasies (GFM) Registry.

Sophie Park, MD, V. Andrieu, R. Sapena, G. Leroux, A. Stamatoullas, M.P. Callat, O. Beyne-Rauzy, J. Mairesse, M.P. Chaury, Herve Dombret, V. Siguret, Norbert Vey, G. Lepeu, A. Guerci, S. Cheze, Pierre Fenaux, F. Dreyfus

Blood (2007) 110 (11): 2456.

https://doi.org/10.1182/blood.V110.11.2456.2456

Published: 2007

Journal Articles

Lenalidomide (LEN) in INT 2 and High Risk MDS with DEL 5q. Interim Results of a Phase II Trial by the GFM.

S. Burcheri, MD, T. Prebet, MD, O. Beyne-Rauzy, MD, R.M. Mbida, MD, N. Hoarau, MD, L. Legros, MD, C. Ravoet, MD, F. Dreyfus, MD, A. Stamatoullas, MD, M.P. Chaury, MD, J. Delaunay, MD, G. Laurent, MD, N. Vey, MD, L. Ades, MD, C. Gardin, MD, Pierre Fenaux, MD

Blood (2007) 110 (11): 820.

https://doi.org/10.1182/blood.V110.11.820.820

Published: 2007

Journal Articles

Prognostic Factors and Response Duration in 419 MDS Treated with Erythropoietin±GCSF: The GFM Experience.

Blood (2006) 108 (11): 522.

https://doi.org/10.1182/blood.V108.11.522.522

Published: 2006

Journal Articles

RBC Transfusions and Iron Chelation Therapy in Clinical Practice in MDS: A One Month Survey by the GFM.

Christian Rose, MD, A. Stamatoulas, MD, D. Vassilief, MD, S. Brechignac, MD, O. Beyne-Rauzy, MD, F. Courtois, MD, M. Wemeau, MD, Agnes Guerci, MD, M.P. Chaury, MD, B. Lefs, MD, B. Mahe, MD, L. Roy, MD, Bruno Quesnel, PD, MD, F. Dreyfus, PD, MD, Pierre Fenaux, PD, MD

Blood (2006) 108 (11): 2661.

https://doi.org/10.1182/blood.V108.11.2661.2661

Published: 2006

Journal Articles

Clinical Relevance of Cardiac Iron Overload Estimated by MRI T2* in Regularly Transfused Low Risk MDS.

C. Ferte, MD, O. Ernst, MD PhD, O. Beyne-Rauzy, MD, M.P. Chaury, MD, S. Brechignac, MD, M. Brauner, MD PhD, T. Mirault, MD, K. Kanaan, MD, E. Bourgeois, MD, N. Cambier, MD, Bruno Quesnel, MD PhD, Pierre Fenaux, MD PhD, Christian Rose, MD

Blood (2006) 108 (11): 2666.

https://doi.org/10.1182/blood.V108.11.2666.2666

Published: 2006

Journal Articles

Low Doses of Thalidomide (Thal) in Low Risk MDS with Transfusion-Dependant Anemia: The GFM THAL-SMD-200 Trial.

J. Tamburini, C. Elie, D. Vassilief, M.C. Quarre, O. Beyne-Rauzy, M. Gardembas, A. Aouba, C. Berthou, L. Sanhes, A. Guerci, A. Stamatoullas, F. Bauduer, J.J. Sotto, L. Legros, S. Vaultier, P. Fenaux, F. Dreyfus, D. Bouscary

Blood (2006) 108 (11): 2673.

https://doi.org/10.1182/blood.V108.11.2673.2673

Published: 2006

Journal Articles

Is There a Role for ATRA in Combination to EPO in Lower Risk Myelodysplastic Syndrome? Preliminary Results of a Phase II Study.

Blood (2005) 106 (11): 2537.

https://doi.org/10.1182/blood.V106.11.2537.2537

Published: 2005

NARROW

MDS with Isolated Neutropenia or Thrombocytopenia. Incidence and Characteristics in the Groupe Francophone des Myélodysplasies (GFM) Registry.

Lenalidomide (LEN) in INT 2 and High Risk MDS with DEL 5q. Interim Results of a Phase II Trial by the GFM.

Prognostic Factors and Response Duration in 419 MDS Treated with Erythropoietin±GCSF: The GFM Experience.

RBC Transfusions and Iron Chelation Therapy in Clinical Practice in MDS: A One Month Survey by the GFM.

Clinical Relevance of Cardiac Iron Overload Estimated by MRI T2* in Regularly Transfused Low Risk MDS.

Low Doses of Thalidomide (Thal) in Low Risk MDS with Transfusion-Dependant Anemia: The GFM THAL-SMD-200 Trial.

Is There a Role for ATRA in Combination to EPO in Lower Risk Myelodysplastic Syndrome? Preliminary Results of a Phase II Study.

Email alerts

ASH Publications

American Society of Hematology

MDS with Isolated Neutropenia or Thrombocytopenia. Incidence and Characteristics in the Groupe Francophone des Myélodysplasies (GFM) Registry.

Lenalidomide (LEN) in INT 2 and High Risk MDS with DEL 5q. Interim Results of a Phase II Trial by the GFM.

Prognostic Factors and Response Duration in 419 MDS Treated with Erythropoietin±GCSF: The GFM Experience.

RBC Transfusions and Iron Chelation Therapy in Clinical Practice in MDS: A One Month Survey by the GFM.

Clinical Relevance of Cardiac Iron Overload Estimated by MRI T2* in Regularly Transfused Low Risk MDS.

Low Doses of Thalidomide (Thal) in Low Risk MDS with Transfusion-Dependant Anemia: The GFM THAL-SMD-200 Trial.

Is There a Role for ATRA in Combination to EPO in Lower Risk Myelodysplastic Syndrome? Preliminary Results of a Phase II Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only